Previous 10 | Next 10 |
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Theravance Biopharma, Inc. 2021 Q1 - Results - Earnings Call Presentation
Image source: The Motley Fool. Theravance Biopharma Inc (NASDAQ: TBPH) Q1 2021 Earnings Call May 4, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Theravance Biopharma Inc (TBPH) Q1 2021 Earnings Call Transcript
Theravance Biopharma, Inc. (TBPH) Q1 2021 Earnings Conference Call May 04, 2021 05:00 PM ET Company Participants Gail Cohen - Vice President, Corporate Communications Rick Winningham - Chief Executive Officer Rick Graham - Senior Vice President, Development Frank Pasqualone - Chief Business O...
Theravance Biopharma (TBPH): Q1 GAAP EPS of -$1.24 misses by $0.16.Revenue of $14.26M (-28.2% Y/Y) misses by $3.01M.2021 Financial Guidance: Operating Expenses (excluding share-based compensation): The Company expects full year 2021 R&D expense of $195 million to $225 million, and SG...
Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update - Company completed enrollment for Phase 2 nezulcitinib (TD-0903, COVID lung hyperinflammation) and Phase 2b izencitinib (ulcerative colitis) studies, is near completion of enrol...
Theravance Biopharma to Report First Quarter 2021 Financial Results on May 4, 2021 PR Newswire DUBLIN , April 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, deve...
An arbitrator has ruled that Innoviva (INVA) did not breach an LLC agreement with Theravance Biopharma (TBPH) over royalties related to sales of GlaxoSmithKline's (GSK) asthma inhaler Trelegy.The LLC, Theravance Respiratory Company ("TRC"), was established when the former Thervance (prio...
In a regulatory filing, Theravance Biopharma ([[TBPH]] -0.4%) has disclosed the departure of its Senior Vice President and Chief Medical Officer Brett Haumann effective April 5, 2021, due to personal circumstances.Even though Theravance notes that the decision was not related to any disa...
Theravance Biopharma recently reported fourth quarter results and posted some encouraging trial news. The company has some assets gaining sales traction and interesting pipeline candidates as well. We update our investment thesis on Theravance given recent results and news in the ...
TD-0903, an inhaled pan-JAK inhibitor being developed by Theravance Biopharma ([[TBPH]] -3.4%) has demonstrated a favorable impact in hospitalized patients with severe COVID-19, according to data from a Phase 2 trial.The findings published in a pre-print pending a peer-review indica...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...